000874644 001__ 874644
000874644 005__ 20220930130233.0
000874644 0247_ $$2doi$$a10.1002/trc2.12001
000874644 0247_ $$2Handle$$a2128/25100
000874644 0247_ $$2altmetric$$aaltmetric:79014672
000874644 0247_ $$2pmid$$apmid:32211506
000874644 0247_ $$2WOS$$aWOS:000751652300062
000874644 037__ $$aFZJ-2020-01563
000874644 082__ $$a610
000874644 1001_ $$0P:(DE-Juel1)159137$$aKutzsche, Janine$$b0$$ufzj
000874644 245__ $$aSafety and pharmacokinetics of the orally available antiprionic compound PRI‐002: A single and multiple ascending dose phase I study
000874644 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2020
000874644 3367_ $$2DRIVER$$aarticle
000874644 3367_ $$2DataCite$$aOutput Types/Journal article
000874644 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1592489354_23512
000874644 3367_ $$2BibTeX$$aARTICLE
000874644 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000874644 3367_ $$00$$2EndNote$$aJournal Article
000874644 520__ $$aIntroductionPRI‐002 is an orally available anti–amyloid beta (Aβ) prionic compound developed for direct disassembly of toxic Aβ oligomers relevant to Alzheimer's disease.MethodsTwo placebo‐controlled clinical phase I trials with oral dosing of PRI‐002 were conducted in healthy young subjects: A single ascending dose trial (4, 12, 36, 108, or 320 mg PRI‐002 or placebo) in 40 participants followed by a multiple ascending dose study with daily 160 mg PRI‐002 for 14 days or 320 mg for 28 days in 24 participants. The main objectives were safety, tolerability, and evaluation of pharmacokinetic (PK) parameters.ResultsPRI‐002 was safe and well tolerated after single and multiple oral administration up to the highest doses. PRI‐002 was absorbed rapidly and drug exposure increased proportional to dose. During repeated daily administration, the drug accumulated by a factor of about three. Steady‐state conditions were reached after 1 to 2 weeks.ConclusionsThe safety and PK results encourage further clinical development of PRI‐002.
000874644 536__ $$0G:(DE-HGF)POF3-553$$a553 - Physical Basis of Diseases (POF3-553)$$cPOF3-553$$fPOF III$$x0
000874644 588__ $$aDataset connected to CrossRef
000874644 7001_ $$0P:(DE-Juel1)144626$$aJürgens, Dagmar$$b1$$ufzj
000874644 7001_ $$0P:(DE-Juel1)144347$$aWilluweit, Antje$$b2$$ufzj
000874644 7001_ $$0P:(DE-HGF)0$$aAdermann, Knut$$b3
000874644 7001_ $$0P:(DE-HGF)0$$aFuchs, Carola$$b4
000874644 7001_ $$0P:(DE-Juel1)171391$$aSimons, Stefanie$$b5$$ufzj
000874644 7001_ $$0P:(DE-HGF)0$$aWindisch, Manfred$$b6
000874644 7001_ $$0P:(DE-HGF)0$$aHümpel, Michael$$b7
000874644 7001_ $$0P:(DE-HGF)0$$aRossberg, Wolfgang$$b8
000874644 7001_ $$0P:(DE-HGF)0$$aWolzt, Michael$$b9
000874644 7001_ $$0P:(DE-Juel1)132029$$aWillbold, Dieter$$b10$$eCorresponding author$$ufzj
000874644 773__ $$0PERI:(DE-600)2832891-7$$a10.1002/trc2.12001$$gVol. 6, no. 1$$n1$$pe12001$$tAlzheimer's & dementia / Translational research & clinical interventions Translational research & clinical interventions [...]$$v6$$x2352-8737$$y2020
000874644 8564_ $$uhttps://juser.fz-juelich.de/record/874644/files/Invoice_R-2020-00374.pdf
000874644 8564_ $$uhttps://juser.fz-juelich.de/record/874644/files/Autorenmanuskript%20Safety%20and%20Pharmacokinetics%20of%20the%20Orally%20Available%20Antiprionic%20Compound%20PRI-002%20A%20Single%20and%20Multiple%20Ascending%20Dose%20Phase%20I%20Study.pdf$$yOpenAccess
000874644 8564_ $$uhttps://juser.fz-juelich.de/record/874644/files/Invoice_R-2020-00374.pdf?subformat=pdfa$$xpdfa
000874644 8564_ $$uhttps://juser.fz-juelich.de/record/874644/files/trc2.12001.pdf$$yOpenAccess
000874644 8564_ $$uhttps://juser.fz-juelich.de/record/874644/files/Autorenmanuskript%20Safety%20and%20Pharmacokinetics%20of%20the%20Orally%20Available%20Antiprionic%20Compound%20PRI-002%20A%20Single%20and%20Multiple%20Ascending%20Dose%20Phase%20I%20Study.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000874644 8564_ $$uhttps://juser.fz-juelich.de/record/874644/files/trc2.12001.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000874644 8767_ $$8R-2020-00374$$92020-05-26$$d2020-05-29$$eAPC$$jZahlung erfolgt$$lDEAL: Wiley$$pTRCI-D-19-00096$$zBelegnr. 1200153579
000874644 909CO $$ooai:juser.fz-juelich.de:874644$$popenCost$$pVDB$$pdriver$$pOpenAPC$$popen_access$$popenaire$$pdnbdelivery
000874644 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)159137$$aForschungszentrum Jülich$$b0$$kFZJ
000874644 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)144626$$aForschungszentrum Jülich$$b1$$kFZJ
000874644 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)144347$$aForschungszentrum Jülich$$b2$$kFZJ
000874644 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)171391$$aForschungszentrum Jülich$$b5$$kFZJ
000874644 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132029$$aForschungszentrum Jülich$$b10$$kFZJ
000874644 9131_ $$0G:(DE-HGF)POF3-553$$1G:(DE-HGF)POF3-550$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lBioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences$$vPhysical Basis of Diseases$$x0
000874644 9141_ $$y2020
000874644 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000874644 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000874644 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000874644 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000874644 915__ $$0LIC:(DE-HGF)CCBYNC4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial CC BY-NC 4.0
000874644 9201_ $$0I:(DE-Juel1)IBI-7-20200312$$kIBI-7$$lStrukturbiochemie$$x0
000874644 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000874644 980__ $$ajournal
000874644 980__ $$aVDB
000874644 980__ $$aUNRESTRICTED
000874644 980__ $$aI:(DE-Juel1)IBI-7-20200312
000874644 980__ $$aI:(DE-Juel1)INM-4-20090406
000874644 980__ $$aAPC
000874644 9801_ $$aAPC
000874644 9801_ $$aFullTexts